Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by Smokey1958on Mar 05, 2021 2:05pm
274 Views
Post# 32729876

Approval for Testing vs Authorization for Use

Approval for Testing vs Authorization for UseFinding the right test site is imperative because they need individuals that are, unfortunately, covid positive to substantiate AcuVid. As such they would need approval to use the device at a clinic or testing site in Toronto that is in an area with the highest incidence of infection and positivity rates.

They ALREADY know AcuVid works in a lab setting, thus the numbers 86% specificity and 100% sensitivity. With the sensitivity set at the standard of high viral load ....regardless of the degree of symptoms. Presumably they would want a test site where all the individuals appear symptomatic regardless of outcome (allergy, cold, flu, covid positive).

Sensitivity: the ability of a test to correctly identify patients with a disease. Specificity: the ability of a test to correctly identify people without the disease. True positive: the person has the disease and the test is positive.

What could go wrong? Actually at this stage it's hard to imagine what would lead to a different outcome in the on-site testing.

AcuVid appears to have a higher sensitivity rating then any rapid point of care test that has currently been authorized by HC or the FDA .....and its a saliva sample. It's equally hard to imagine it not being approved provided there are no surprises in the testing.

The attack on the stock and thus the sp should not, in any way, reduce the anticipation or excitement at the prospect of a significant reward for being patient.

GLTA!!!
<< Previous
Bullboard Posts
Next >>